Neuland Laboratories Ltd PE Ratio

Neuland Laboratories PE Ratio

Image

Neuland Laboratories Ltd

NSE: NEULANDLAB

PE

59

Last updated on: Sep 19, 2026

Key Highlights

  • The P/E Ratio of Neuland Laboratories Ltd is 59 as of 19 Sep 15:30 PM The P/E Ratio of Neuland Laboratories Ltd changed from 33.4 on March 2021 to 42.6 on March 2026 . This represents a CAGR of 4.14% over 6 years The Latest Trading Price of Neuland Laboratories Ltd is ₹ 22875 as of 18 Sep 15:30 The PE Ratio of Pharmaceuticals Industry has changed from 24.6 to 32.4 in 5 years. This represents a CAGR of 5.66% The PE Ratio of Automobile industry is 12.7. The PE Ratio of Finance industry is 16.5. The PE Ratio of IT - Software industry is 18.5. The PE Ratio of Pharmaceuticals industry is 31.7. The PE Ratio of Retail industry is 88.6. The PE Ratio of Textiles industry is 36.7 in 2026 .

Historical P/E Ratio of Neuland Laboratories Ltd

No data available

Company Fundamentals for Neuland Laboratories Ltd

Image

Neuland Laboratories Ltd

NSE: NEULANDLAB

Share Price

₹ 22875.7

219.50 (0.97%)

stock direction

Last updated on: Sep 18, 2026

Market Price of Neuland Laboratories Ltd

1M

1Y

3Y

5Y

Monitoring Neuland Laboratories Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
18 Sep 202622875.7
17 Sep 202622656.2
16 Sep 202622653.1
15 Sep 202622522.85
11 Sep 202623536.2
10 Sep 202623803.85
09 Sep 202623250.3
08 Sep 202623973.7
07 Sep 202622872.35
04 Sep 202622643.3

SWOT Analysis Of Neuland Laboratories Ltd

Strength

5

che

Weakness

2

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Neuland Laboratories Ltd

Asset Value vs Market Value of Neuland Laboratories Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Neuland Laboratories Ltd29349
Sun Pharmaceutical Industries Ltd440398
Divis Laboratories Ltd248664
Torrent Pharmaceuticals Ltd182738
Zydus Lifesciences Ltd115012
Cipla Ltd110794

PE Ratio of Neuland Laboratories Ltd Explained

29349

Market cap

497

Earnings

59.0X

PE Ratio

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Neuland Laboratories Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Neuland Laboratories Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Neuland Laboratories Ltd

No data available

* All values are in %

About Neuland Laboratories Ltd

  • Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao.
  • The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin.
  • Neuland Drugs & Pharmaceuticals Pvt.
  • Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992.
  • NLL manufactures bulk drugs. The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix.

Neuland Laboratories Ltd News Hub

Neuland Laboratories consolidated net profit rises 58.16% in the June 2024 quarter

Net profit of Neuland Laboratories rose 58.16% to Rs 97.87 crore in the quarter ended June 2024 as a

Read more

01 Aug 24

Neuland Laboratories to declare Quarterly Result

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 6 November 2024

Read more

18 Oct 24

Neuland Laboratories consolidated net profit declines 63.20% in the September 2024 quarter

Net profit of Neuland Laboratories declined 63.20% to Rs 32.84 crore in the quarter ended September

Read more

06 Nov 24

Neuland Laboratories Ltd leads losers in 'A' group

Hindustan Zinc Ltd, Five-Star Business Finance Ltd, Great Eastern Shipping Company Ltd and Triveni E

Read more

06 Nov 24

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions